SCHEMBL793778

SCHEMBL793778

O=C1c2ccccc2CCN1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
CES1 P23141 1/20 0.44
BCAT2 O15382 2/20 0.43
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
DRD1 P21728 1/20 0.40
DRD3 P35462 1/20 0.40
ACHE P22303 1/20 0.40
CYP2A6 P11509 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ALDH1A1 P00352 1/20 0.40
RNASEH1 O60930 1/20 0.40
HTR2C P28335 4/20 0.39
HTR2B P41595 4/20 0.39
HTR2A P28223 3/20 0.39
SIGMAR1 Q99720 1/20 0.38
SRD5A1 P18405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL123507 0.82 KMT2A (0.44) KMT2ACES1BCAT2NR1H2NR1H3
SCHEMBL30374421 0.81 KMT2A (0.57) KMT2ANPC1RAB9AALDH1A1RNASEH1
SCHEMBL149618 0.81 KMT2A (0.57) KMT2ANPC1RAB9AALDH1A1RNASEH1
Hydrochloric Acid SCHEMBL30331576 0.80 KMT2A (0.55) KMT2ANPC1RAB9AALDH1A1RNASEH1
SCHEMBL24786745 0.79 KMT2A (0.42) KMT2ACES1BCAT2NR1H2NR1H3
SCHEMBL15467684 0.78 NR1H2 (0.42) KMT2ACES1BCAT2NR1H2NR1H3
SCHEMBL798331 0.76 KMT2A (0.48) KMT2ACES1BCAT2DRD3CYP2A6
SCHEMBL29965051 0.76 KMT2A (0.48) KMT2ACES1BCAT2DRD3CYP2A6
SCHEMBL21591322 0.75 ACHE (0.49) DRD1DRD3ACHENPC1RAB9A
Formic Acid SCHEMBL30331996 0.75 KMT2A (0.49) KMT2ANR1H2NR1H3DRD1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 KMT2A 660/4885CES1 108/4885BCAT2 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.